Combination therapy to overcome resistance

 

We search for new applications for existing or abandoned drugs through the use of functional genomic approaches. By using existing drugs, we limit development cost, which allows us to bring these drugs to patients at sustainable prices.
As a first proof of concept, we have identified a new indication for Qamelostat (suberoylanilide hydroxamic acid), which is currently undergoing clinical testing.

 

Cancer is an adaptable enemy, and a significant challenge to the development of successful targeted therapies is the "universal, but not futile" problem of resistance

Charles Sawyer, MD President of the American Association of Cancer research at the 2013 American Society of Clinical Oncology Annual meeting plenary lecture

 
 

Pre clinical Proof of concept

See how resistance against a B-Raf inhibitor in B-Raf mutant colon cancer was overcome using shRNA screens

Learn More →

Clinical Development

And how this pre clinical concept was translated into a successful clinical trial

Find Out How →